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The development of new radioiodinated ligands for imaging the muscarinic acetylcholinergic com-
plex ~mAChR! using single photon emission computed tomography ~SPECT! requires the evalua-
tion of human organ doses prior to approval for human use. Animal biodistribution and excretion
data were obtained and evaluated for IPIP, a new mAChR agent. Preliminary biodistribution studies
were performed on four different stereoisomers of IPIP. A biokinetic model of the Z-(S)-IPIP
stereoisomer was constructed for the rat and used to estimate the internal absorbed dose in humans
based on an extrapolation of the rat model. The thyroid is the critical organ for this radiopharma-
ceutical, with an absorbed dose estimate of 2.4 mGy/MBq for both males and females, when
labeled with 123I. Even when blocked, the thyroid is still the critical organ, yet with a 90% dose
reduction. The heart and brain receive the next highest doses in both males and females. Effective
dose estimates for the use of pure 123I-PIP in humans are 0.16 mSv/MBq for males and 0.14
mSv/MBq for females. The biodistribution studies of the Z-(S)-IPIP stereoisomer showed the most
promise as a successful agent for imaging muscarinic receptor sites in the heart and brain. IPIP also
demonstrated potential as a therapeutic radiopharmaceutical for some colon carcinomas where
muscarinic receptor sites are expressed in the tumor cells. These results provide preliminary data
for use of IPIP in clinical studies on humans. © 2000 American Association of Physicists in
Medicine. @S0094-2405~00!01704-1#
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The development of new radioiodinated ligands to be uti-
lized in the imaging of the muscarinic acetylcholinergic
complex ~mAChR! by single photon emission computed to-
mography ~SPECT! requires the evaluation of human organ
doses prior to approval for use in humans. The availability of
a mAChR subtype-specific imaging agent, which would pro-
vide cross-sectional data on the density of the various
mAChR subtypes, is expected to have important implications
in evaluating early changes in mAChR and in the effective-
ness of new therapeutic strategies. These mAChR subtypes
are found in various organs to different degrees throughout
the body and have been postulated to play an important role
in memory, aging, learning, and heart function. In addition,
they are also important in various dementias such as Alzhe-
imer’s and Parkinson’s disease.1 Several radioiodinated
ligands @3-quinuclidinyl 4-iodobenzilate ~4IQNB!, iododex-
itimide and 3-quinuclidinyl a-hydroxy-a-iodopropenyl-a-
phenylacetate ~IQNP!# have been developed as potential
probes for mAChR.2 However, none of these displays the
desired subtype selectivity required for the detailed study of778 Med. Phys. 27 4, April 2000 0094-2405Õ2000Õ27mAChR. Recently, a new radioiodinated ligand has been de-
veloped in which the quinuclidinyl ring of IQNP was re-
placed with a N-methylpiperidinyl ring thus forming ~IPIP!.
The main difference between the IQNP and the IPIP struc-
tures ~see Fig. 1! is that the IPIP molecule has a methyl
group attached to the nitrogen molecule, whereas IQNP lacks
this feature. Alzheimer’s disease has been linked with the
loss of cholinergic receptors1 which also function in various
types of lung and colon carcinomas. Therefore, the ability to
image the various subtypes of mAChR will potentially allow
for early diagnosis and the ability to evaluate treatments to
better understand the biological role of the mAChR. Further-
more, the possibility exists for developing therapeutic
receptor-selective agents to target certain colon and lung car-
cinomas having high concentrations of muscarinic receptors.
As observed with other examples from this class of com-
pound, the racemic ligand contains four stereoisomers. We
observed that each stereoisomer demonstrates significantly
different biological properties such as receptor binding site
and mode of excretion. In this work, we have measured the
biodistribution and excretion rates of a new radioiodinated7784Õ778Õ9Õ$17.00 © 2000 Am. Assoc. Phys. Med.
779 Breeden III et al.: In vivo biodistribution 779selective mAChR agent in laboratory rats and have used
these data to estimate the organ-specific radiation doses to
humans. The brain muscarinic receptor concentrations in hu-
mans ~;600 fmol/mg!3 and rats ~;800 fmol/mg!4 are com-
parable. Thus, the rat is an appropriate animal for use in
preliminary dose estimates to humans from radiolabeled in-
jections of IPIP.
A number of animal biodistribution studies were required
to evaluate each isomer of IPIP to determine which, if any, is
best suited for clinical investigations. Each preliminary study
utilized five rats in each of four time points to determine the
isomer of choice. For the particular isomer which displayed
the highest mAChR binding and the optimum receptor sub-
type specificity in rats, more detailed male and female bio-
distribution and excretion studies were performed in order to
estimate internal dose extrapolated to humans. The extrapo-
lated human dose was estimated using the MIRD technique.
Knowing the internal dosimetry in humans will allow for
maximum benefit to patients from these new radiopharma-
ceuticals.
II. MATERIALS AND METHODS
A. Preliminary biodistribution studies
This study was conducted at the Oak Ridge National
Laboratory with several preliminary animal studies involving
the four stereoisomers of IPIP @E-(R)-IPIP, E-(S)-IPIP,
Z-(R)-IPIP, and Z-(S)-IPIP#. Following radioiodination,
purification by high-performance liquid chromatography
~HPLC!, and thin-layer chromatography ~TLC! analysis,5
each agent, in a saline solution, was administered to five
female Fischer Virus Antibody-Free ~VAF! rats via a lateral
tail vein. The rats were sacrificed following anesthetization
by metophane at the designated time points. The activity
administered to each animal ranged from 0.15 to 0.19 MBq
of 125IPIP in volumes of about 0.4 to 0.5 mL. It was con-
cluded that this amount of activity would give a statistically
sufficient number of counts in the organs that were to be
studied and that its radiotoxicity level would be insignificant.
The radiological purity of the compound was determined
through use of a shielded germanium detector prior to ad-
ministration. The uptake of radioactivity in the major organs
in groups of five animals per time period was determined.
FIG. 1. Structural differences between IPIP and IQNP.Medical Physics, Vol. 27, No. 4, April 2000The time points used in the evaluation of the four stereoiso-
mers ranged from 15 to 240 min. The major organs ~i.e.,
liver, kidney, heart, lung, thyroid, blood, and brain! were
removed, rinsed with saline, blotted dry, weighed with a
digital analytical balance, and analyzed by gamma spectros-
copy. The brain was removed and dissected into the various
regions of interest, including the cerebellum, pons, medulla,
cortex, striatum, hippocampus, thalamus, superior colliculi,
inferior colliculi, and its remainder. Results were expressed
as percent injected activity of the radioiodinated agent per
organ ~%IA! for the selected time points. The data were ana-
lyzed to determine which one of the four stereoisomers was
the best candidate for future imaging studies in humans. This
was based primarily on the amount of activity seen in the
brain and heart because these were the main two organs for
which this agent would be utilized in nuclear medicine im-
aging. Other organs, however, were also studied to gain ba-
sic knowledge of the biodistribution properties of IPIP.
Since the rat thyroid is extremely small and the entire
volume of blood was impossible to collect, these masses
were estimated based on fractional estimates found in the
literature. Total blood and thyroid masses in the rat were
assumed to be 5 and 0.0075 percent of the whole-body mass,
respectively.6 In addition to being very small, the rat thyroid
is difficult to distinguish from skeletal muscle, therefore, a
sample of muscle containing the thyroid was taken from the
throat area. The organs were counted using a Packard Minaxi
5000 automatic g-counter consisting of a NaI detector
coupled to an MCA with a window setting from 15 to 80
keV.
Once the preliminary studies of each of the four stereoi-
somers of IPIP were complete, the data were analyzed to
determine which agent had the highest brain and heart up-
take. The Z-(S)-IPIP stereoisomer showed the most promise
for potential human imaging studies, therefore, detailed bio-
distribution studies were conducted on this agent.
B. Detailed biodistribution studies
Following a verification of the Z-(S)-IPIP stereoisomer’s
purity using thin-layer chromatography,5 the first detailed
biodistribution study for dosimetry purposes was performed,
again using the female Fischer VAF rats. Seven time points
between 15 and 7200 min were used with four animals per
time point. All animals were allowed food and water ad li-
bitum both prior to the injections and during the time interval
between injection and sacrifice. The ligand was administered
in a saline solution via the lateral tail vein, and the rats were
sacrificed by cervical dislocation following anesthetization
by metophane at the designated time points. The radioiodi-
nated yield of the compound was determined using a
shielded high purity germanium ~HPGe! detector prior to
administration.
The activity was administered to all animals, which were
then sacrificed at the following time points: 15, 30, 60, 240,
480, 1770, and 7200 min. The selected organs were re-
moved, rinsed with saline, blotted dry, weighed, and counted
to determine the percent injected activity per organ. The
780 Breeden III et al.: In vivo biodistribution 780FIG. 2. Female rat biokinetic model.organs/tissues studied included the liver, kidneys, heart,
lungs, thyroid, blood, global brain, stomach wall, small in-
testine wall, cecum wall, large intestine wall, spleen, ovaries,
adipose tissue, skeletal muscle, pancreas, adrenal glands,
uterus, cortical bone, bladder wall, stomach contents, small
intestine contents, cecum contents, large intestine contents,
and the remainder of the carcass. Again, the organs were
counted on the automated NaI system. The carcass, however,
due to its large size, was counted separately on the HPGe
system.
The four rats comprising the 7200 min time point were
housed individually in separate metabolism cages. Urine and
feces from these rats were collected daily for five days after
injection to evaluate the route and kinetics of excretion of the
radioactivity. On the fifth day, the animals were sacrificed
and the same organ retrieval sequence was followed as in
earlier time points. The activity found in the organs, carcass,
and urine/feces samples also was integrated to determine
whether all of the activity injected could be accounted for in
each animal.
After the detailed female biodistribution study was com-
pleted, an identical study was performed on male Fischer
VAF rats. The same time points and sampling protocol were
used for these animals. The only organ removal changes
were that the testes were taken from males in place of the
ovaries and uterus taken from females. The activity was ad-
ministered to each male rat which were then sacrificed at the
following time points: 15, 30, 60, 240, 480, 1770, and 7200
min.
C. Dual blocking biodistribution study
Since the results of our biodistribution studies demon-
strated significant thyroid uptake of activity, another rat ex-Medical Physics, Vol. 27, No. 4, April 2000periment was performed on male rats to assess thyroid up-
take of Z-(S)-IPIP following blocking with Lugol’s solution
~potassium iodide!. Four male Fisher VAF rats were pre-
injected with 2 mg of KI ~based on the ratio of rat thyroid
mass to body mass! 30 min prior to injection of approxi-
mately 0.19 MBq of Z-(S)-IPIP in 0.4 mL saline. The ani-
mals were then sacrificed at 120 min and the same organs
were retrieved as in the biodistribution study. Four control
animals were injected with approximately 0.19 MBq of
Z-(S)-IPIP in 0.4 mL saline. This control group was also
sacrificed at 120 min and the same organs were retrieved.
This study was designed to determine whether the IPIP mol-
ecule or a metabolized form of IPIP was accumulating in the
organs/tissues.
Finally, another group of male rats was administered
QNB,7 a nonradioactive agent similar to IPIP that would
block a majority of the muscarinic receptor sites that IPIP
would bind to in the various organs. When an organ with a
normally high %IA/g showed a reduction in activity follow-
ing administration of QNB, it was theorized that IPIP was
binding to these muscarinic receptor sites, as opposed to free
iodine. Four male rats were pre-injected with 2 mg/kg of
QNB 30 min prior to injection of approximately 0.19 MBq
of Z-(S)-IPIP in 0.4 mL saline. The animals were then sac-
rificed at 120 min and dissected.
D. Biokinetic model
Functions of activity vs. time were developed to fit the
biodistribution data in order to determine organ residence
times. To develop these functions, a multi-compartmental
model of the transfer rates of the activity throughout the
major organs of the rat was designed. The model for the
female rat contained 17 compartments ~Fig. 2! and the model
781 Breeden III et al.: In vivo biodistribution 781for the male rat contained 16 compartments. The male rat
model is identical to that of the female except that the two
compartments representing the ovaries and uterus are re-
placed with a single compartment representing the testes.
The SAAM II software was used to construct and solve the
biokinetic model.8 First-order differential equations were
used to express the rate of change in activity with time for a
particular organ,
dA2
dt 5@k2,1A1~ t !#2@k1,2A2~ t !#2lA2~ t !, ~1!
where ki , j represents the transfer coefficient ~or clearance
rate! in units of percent injected activity per unit time trans-
ferred from compartment j to compartment i, and l is the
radioactive decay constant, also in units of inverse time.
Once the model was solved and the best fit of the transfer
coefficients to the data was obtained, the software ACTLITE9
is used to calculate the residence times. The transfer coeffi-
cients for the various compartments are input into the soft-
ware and the software integrates the activity in the organ
over the time for the modeled clearance rates to estimate
residence times. Residence times of IPIP in each organ were
then determined using transfer coefficients and integrating
activity over time. Residence times determined from experi-
mental data with 125I were decay corrected for 123I.
From the detailed male and female biodistribution studies,
in addition to the urine and fecal excretion studies, graphs of
percent injected activity versus time were plotted for each
organ studied. From these curves, the residence time was
calculated for each organ or tissue. These activities were also
decay corrected for 125I to 123I with the following equation:
A123~ t i!5A125~ t i!el123t ie2l125t i, ~2!
where A(t i) is the activity at the ith time of sampling, and
l123 and l125 are the radiological decay constants for 123I and
125I, respectively. These transfer coefficients from the ex-
trapolated human model were used to estimate integral activ-
ity residence times and, using the MIRD procedure,10 to es-
timate internal dose to humans. The extrapolation
methodology is described later.
E. Internal dosimetry
With estimates of the residence time, the internal radia-
tion doses were calculated using the MIRD formulation.11
Values of S were calculated using ICRP 2312 organ weights,
the SEECAL13 program, the MIRD Nuclear Decay Data,14 and
appropriate specific absorbed fractions.13,15
The biodistribution data, collected using laboratory ani-
mals, can either be directly applied to man or extrapolated to
man in a manner which attempts to address the anatomical
and physiological differences between man and the labora-
tory animal. Roedler16 outlined such an extrapolation proce-
dure for residence times in a model-free manner. The resi-
dence time in a compartment ~or tissue! of a
multicompartmental model is a complex function of the
model’s transfer coefficients. It was assumed that the model
structure indicated by the animal data provides a proper char-Medical Physics, Vol. 27, No. 4, April 2000acterization of the underlying physiological processes.
Therefore, extrapolation of the individual transfer coeffi-
cients between animal and man was carried out rather than
extrapolation of the residence times. The transfer coefficients
are viewed as the fundamental measures of the kinetic pro-
cesses and the extrapolated model retains an accounting of
the competitive nature of the processes governing the behav-
ior of the age in the body. It is noted, however, that residence
times calculated from our extrapolated model may differ
from values derived by extrapolating the animal’s residence
time to man in a model-free manner. The correction factor
for all transfer coefficients for movement from the blood to
the various organs took the form,
CF15
M HOM RTB
M ROM HTB
, ~3!
where M HO is the mass of the human organ, M HTB is the
mass of the human total body, M RO is the mass of the rat
organ, and M RTB is the mass of the rat’s total body. This
factor corrects for the variation of mass fraction between the
organ and total body in the human and the rat. For example,
if a particular organ is of higher mass fraction in the human
than in the animal, then these transfer coefficients are higher
in the human than in the rat.
For movement of activity from an organ compartment
~except the small-intestine contents! to the blood and from
the G.I. walls to the G.I. contents, all transfer coefficients
were corrected by
CF25S M RTBM HTBD
0.75
, ~4!
where 0.75 is an empirically determined value16 which rep-
resents the power of a function used to describe the meta-
bolic differences among mammals, yet between species.
Therefore, this factor will correct for the slower metabolism
of the drug in humans versus rats by lowering the transfer
coefficients. Thus, the turnover rates for the drug will be
lower in humans than in rats based on this attempt to ex-
trapolate over metabolism differences between the two spe-
cies.
For the transfer coefficient of movement from the S.I.
contents to the blood, the following manipulation was made:
k ~Blood←S.I. Contents!5
f 1k ~U.L.I. Contents←S.I. Contents!
~1.02 f 1! , ~5!
where k ~U.L.I. Contents←S.I. Contents! is a constant17 of 6d21 and
f 1 is
f 15
k ~Blood←S.I. Contents!
k ~Blood←S.I. Contents!1k ~L.I. Contents←S.I. Contents!
. ~6!
Additionally, changes were made to several transfer coef-
ficients. For example, the transfer coefficient for the route
from blood to urine in the rat model was changed to one
from the blood to the urinary bladder contents and the known
ICRP 6718 transfer coefficient of describing movement from
the urinary bladder contents to the urine was added. Known
ICRP 3017 transfer coefficients from the stomach contents to
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from the U.L.I. contents to the L.L.I. contents, and from the
L.L.I. contents to the faces also were added. Additionally, it
was assumed that all of the activity transferred from blood to
the large intestine in the rat model was transferred from
blood to the U.L.I. in the human model, so as to distinguish
between the U.L.I. wall and the L.L.I. wall, since these two
organs had to be kept as one ~L.I. wall! when modeling rat
physiology.
It is important to note that the dose calculations were
made for 123I instead of 125I since 125I would not be used in
SPECT imaging because of its very low photon energy ~35
keV!. Iodine-123 has a more acceptable photon energy ~159
keV! for SPECT imaging and its use would result in a lower
absorbed dose than 131I. The biodistribution studies were
performed with 125I because of its long half-life and because
its is much less expensive than cyclotron-produced 123I.
The contribution to internal dose due to the contaminant
radionuclides was also determined. These contaminants com-
prise approximately 0.2% of the activity in an 123I sample,
with the majority being 125I. The entire 0.2% of radionuclide
contaminants, therefore, are assumed to be 125I in the
contaminant-dose estimation. Absorbed dose estimates for
the contaminants were determined using the same transfer
coefficients from the biokinetic model for 123I. The contami-
nant dose was estimated for each organ and its overall con-
tribution is approximately 20% of the 123I dose calculated
herein.
III. RESULTS
The results of the preliminary biodistribution studies for
each of the four stereoisomers, expressed as percent injected
activity per gram of organ mass, are given in the Table I.
Table II contains estimates of residence times for various
organs extrapolated to humans, as described, and Table III
provides transfer coefficients determined for 123I-PIP in male
and female rats. Table IV gives internal dose estimates for a
unit injection of 123I-PIP in males and females extrapolated
from the rat model to humans.
IV. DISCUSSION
After performing the initial biodistribution studies on the
four different stereoisomers of IPIP, it was seen that the
Z-(S!-IPIP was the best candidate for future imaging studies
because of its high uptake in the brain and heart. These two
organs are the most important in this evaluation because
these are the main organs in which IPIP would be used for
diagnostic imaging purposes. The Z-(S)-IPIP had a maxi-
mum uptake in the rat heart of 7.361.5%IA/g at 15 min;
whereas the next highest value was given by the Z-(R)-IPIP
of 1.660.1%IA/g. The Z-(S)-IPIP also had approximately
the same or higher uptakes in the various brain regions of
interest compared to the other three stereoisomers. If there
existed some clinical condition in a patient with malfunction-
ing muscarinic receptor sites, these changes would be more
easily imaged using the compound with the highest uptakeMedical Physics, Vol. 27, No. 4, April 2000because it would provide the best imaging characteristics.
Therefore, the Z-(S)-IPIP was chosen to perform the de-
tailed biodistribution studies.
The Z-(S)-IPIP stereoisomer was radiolabeled with 125I
at an overall radiolabeling yield of 86.5%. A preliminary
TLC analysis of the IPIP sample showed that after HPLC
purification, the radiochemical purity was 98%. The other
2% was either free iodide or an iodinated organic molecule
~i.e., starting products of the reaction to make the PIP
ligand!.
The first detailed biodistribution study using female rats
provided some interesting and somewhat unexpected results.
The heart and brain uptakes were basically reproduced, as
seen in the preliminary biodistribution study of the
Z-(S)-IPIP stereoisomer. The small intestine wall at the 1
hour time point reached a maximum percent injected activity
of 11.961.3. In addition, the stomach contents reached a
maximum percent injected activity of 7.960.5 at the 4 hour
time point. From these results, one would expect the stomach
wall to have a large percent injected activity similar to these
values at an earlier time point; however, this was not the
case. The stomach reached a maximum percent injected ac-
tivity (1.360.1) at 1 hour. This process of uptake and depo-
sition in the G.I. tract became the most difficult organ system
to model. The method of uptake and deposition in the G.I.
tract may not be as simple as blood flow to the walled organs
and transfer of contents from one organ to the next along the
tract. The biodistribution studies with the male rats gave
similar results with what was seen in identical organs taken
in the female biodistribution study. The only exception was
that the percent injected activities in the male rats were all
slightly higher than in the female rats.
The biodistribution studies were also able to shed light on
the chemical form in which the radioactivity existed in the
organs. The activity could be in the form of IPIP, a metabo-
lized form of IPIP, or free iodide. The QNB blocking study
seemed to prove that the activity in the heart, brain, thyroid,
L.I. wall, cecum contents, and L.I. contents contained unme-
tabolized IPIP. However, further tissue extraction studies,
that are not yet published, gave more conclusive and reliable
information that the L.I. wall did not contain IPIP and the
S.I. wall did. Therefore, IPIP is not going to muscarinic re-
ceptor sites in the S.I. wall, but possibly some other cholin-
ergic receptor site.
The blocking study with Lugol’s solution proved to be
very effective in blocking the thyroid from free radioactive
iodide. At 120 min, the control group given no Lugol’s had a
percent injected activity of 1.760.4, whereas the group
given Lugol’s had a percent injected activity of 0.1560.13.
This resulted in approximately a 91% reduction in activity
deposited in the thyroid. Therefore, by saturating the human
thyroid with Lugol’s solution, the thyroid would be safely
blocked, greatly reducing its absorbed dose in a normal ad-
ministration of IPIP.
The excretion studies of both the female and male rats
showed that the majority of the activity was excreted in the
first 24 hours. During the first day for females, 5463.8% of
the injected activity was excreted in the urine and
783 Breeden III et al.: In vivo biodistribution 783TABLE I. Results of preliminary biodistribution studies. Percent injected activity per gram of organ ~standard deviations are less than 30%!.
Organ Isomer
Time ~min!
Organ Isomer
Time ~min!
15 30 60 120 180 240 15 30 60 120 180 240
Blood
E-~R!- 0.51 0.49 0.50 0.44 0.31 0.30
Z-~R!- 0.60 0.49 0.43
E-~S!- 0.27 0.25 0.28 0.29 0.26 0.25
Z-~S!- 0.41 0.43 0.39 0.37 0.39 0.32
Liver
E-~R!- 1.2 0.92 0.70 0.51 0.38 0.32
Z-~R!- 1.0 0.37 0.26
E-~S!- 3.0 3.0 3.4 2.7 1.7 1.4
Z-~S!- 1.3 1.3 1.1 0.84 0.71 0.49
Kidney
E-~R!- 1.9 1.3 1.1 0.62 0.36 0.31
Z-~R!- 1.9 0.57 0.33
E-~S!- 2.9 2.1 1.7 1.1 0.67 0.52
Z-~S!- 2.4 2.1 1.4 0.77 0.57 0.43
Heart
E-~R!- 0.80 0.57 0.4 0.25 0.15 0.14
Z-~R!- 1.6 0.39 0.24
E-~S!- 1.2 0.78 0.60 0.36 0.35 0.21
Z-~S!- 7.3 6.0 3.6 2.5 1.1 0.78
Lung
E-~R!- 6.6 3.3 2.2 0.95 0.50 0.39
Z-~R!- 6.6 1.0 0.54
E-~S!- 4.7 3.0 1.5 0.90 0.58 0.45
Z-~S!- 5.8 3.9 2.4 1.3 0.89 0.76
Thyroid
E-~R!- 0.27 0.42 1.2 1.1 2.8 3.8
Z-~R!- 0.20 1.4 3.4
E-~S!- 0.11 0.23 0.42 0.84 1.0 1.8
Z-~S!- 0.14 0.24 0.51 1.2 1.8 2.1
Cerebellum
E-~R!- 1.5 0.84 0.38 0.18 0.09 0.06
Z-~R!- 1.9 0.30 0.12
E-~S!- 1.8 1.3 1.1 0.62 0.36 0.23
Z-~S!- 2.7 2.3 2.3 1.9 1.2 0.91
Pons
E-~R!- 1.9 1.7 0.83 0.77 0.21 0.25
Z-~R!- 3.2 1.6 0.77
E-~S!- 2.1 1.5 0.93 0.70 0.58 0.32
Z-~S!- 3.1 3.3 3.4 3.6 3.4 3.2
Medulla
E-~R!- 1.8 1.3 0.63 0.32 0.15 0.09
Z-~R!- 2.4 0.71 0.31
E-~S!- 1.6 1.5 0.98 0.63 0.53 0.33
Z-~S!- 2.9 3.0 3.0 2.6 2.4 2.0
Cortex
E-~R!- 2.3 1.8 0.99 0.77 0.39 0.36
Z-~R!- 4.8 3.6 2.2
E-~S!- 2.9 1.8 1.4 0.81 0.52 0.39
Z-~S!- 4.8 5.2 4.9 5.5 5.1 5.3
Striatum
E-~R!- 2.2 1.9 0.96 0.76 0.39 0.41
Z-~R!- 3.8 3.5 2.3
E-~S!- 2.6 1.8 1.3 0.79 0.53 0.38
Z-~S!- 3.6 4.1 3.8 4.3 4.2 4.1
Hippocampus
E-~R!- 2.1 1.8 0.96 0.67 0.33 0.34
Z-~R!- 3.5 2.8 2.0
E-~S!- 2.3 1.6 1.3 0.80 0.51 0.36
Z-~S!- 3.0 3.0 3.3 3.8 3.6 3.5
Thalamus
E-~R!- 2.3 1.9 0.83 0.58 0.23 0.21
Z-~R!- 3.7 2.1 1.0
E-~S!- 2.4 1.8 1.1 0.69 0.48 0.32
Z-~S!- 3.4 3.6 3.5 4.2 3.7 3.7
Superior Colliculi
E-~R!- 1.9 1.2 0.62 0.37 0.14 0.10
Z-~R!- 3.7 1.3 0.58
E-~S!- 2.2 1.4 1.1 0.69 0.45 0.29
Z-~S!- 3.7 3.6 3.8 4.4 3.8 3.5
Inferior Colliculi
E-~R!- 1.9 1.0 0.54 0.36 0.14 0.10
Z-~R!- 3.7 1.0 0.48
E-~S!- 2.2 1.5 1.0 0.63 0.37 0.27
Z-~S!- 4.0 3.9 4.2 4.5 3.8 3.38.260.4% of the injected activity was excreted in the feces.
During the first day for males, 3961.4% of the injected ac-
tivity was excreted in the urine and 6.260.9% of the injected
activity was excreted in the feces. This rapid clearance from
the body suggests that low radiation doses, relative to an
iodinated pharmaceutical with a longer clearance time,
should result for most organs, with the possible exception of
higher doses to the excretory organs.
Even though there is a relatively large difference in the
first 24 hour urine excretion data between males and females,
this difference has little effect on the difference between the
absorbed dose estimates for the two genders. The urine ac-
tivity in females is higher than in males for the first 24 hour
time point, but the urine activity in males for the next time
point is slightly higher than in females. Figure 3 shows theMedical Physics, Vol. 27, No. 4, April 200024 hour urinary excretion for 125I and 123I in males and fe-
males. As a result, the area under the two curves and the
residence times for the 123I compound only differ by approxi-
mately 3%.
Several simplifications had to be made to the models in
order to obtain the best fit to the biodistribution data. First,
organs/tissues in which IPIP had only a minor uptake, such
as the muscle, fat, bone, spleen, adrenals, pancreas, lungs,
and carcass, had to be summed over each time point and
treated as one compartment. Furthermore, the cecum and L.I.
wall were combined and treated as the L.I. wall, therefore,
there was no U.L.I. wall and L.L.I. wall separation in the
model.
To generate more reliable estimates of radiation dose in
humans, the transfer coefficients were extrapolated from the
784 Breeden III et al.: In vivo biodistribution 784rat model to a human model. The organ receiving the highest
dose was the thyroid, with an estimated absorbed dose of 2.4
mGy/MBq in both females and males. It is important to note
that under any clinical administration of IPIP the thyroid
TABLE III. Mean transfer coefficients (d21) for 123I-PIP in male and female
rats ~standard deviation in parentheses!.
Transfer route Male Female
Blood→Brain 13 ~1.9! 16.6 ~3.00!
Blood→Heart wall 9.8 ~1.2! 16.9 ~3.31!
Blood→Liver 17 ~2.1! 26.3 ~4.49!
Blood→Stomach wall 2.8 ~0.40! 3.41 ~0.615!
Blood→Small intestine wall 30 ~4.4! 37.7 ~6.52!
Blood→Large intestine wall 11 ~1.2! 12.8 ~2.20!
Blood→Stomach contents 15 ~2.9! 12.3 ~3.41!
Blood→Kidneys 8.3 ~2.2! 11.1 ~3.18!
Blood→Urine 74 ~11! 74.5 ~13.9!
Blood→Thyroid 6.9 ~1.1! 6.94 ~1.44!
Blood→Testes 2.4 ~0.30!
Blood→Ovaries 0.529 ~0.129!
Blood→Uterus 1.82 ~0.348!
Blood→Other 68 ~8.0! 87.2 ~18.8!
Kidneys→Blood 23 ~11! 31.4 ~12.1!
Thyroid→Blood 0.25 ~0.16! 0.208 ~0.0399!
Brain→Blood 2.2 ~0.45! 3.96 ~0.769!
Heart wall→Blood 29 ~2.6! 46.9 ~5.76!
Liver→Blood 11 ~1.2! 16.9 ~1.83!
Testes→Blood 7.7 ~0.97!
Ovaries→Blood 19.7 ~7.54!
Uterus→Blood 18.0 ~3.80!
Large intestine wall→Blood 6.2 ~1.1! 9.82 ~1.28!
Other→Blood 9.52 ~0.766! 11.0 ~2.30!
Small intestine wall→
Small intestine contents
6.01 ~1.10! 12.6 ~1.57!
Stomach wall→Stomach contents 4.12 ~0.758! 5.85 ~1.05!
Stomach wall→Small intestine contents 3.25 ~0.954! 5.15 ~1.97!
Small intestine contents→Blood 16.4 ~3.54! 29.0 ~6.33!
Small intestine contents→
Large intestine contents
6.93 ~0.897! 9.83 ~1.40!
Large intestine contents→Feces 3.33 ~1.23! 3.06 ~0.680!
TABLE II. Residence times for 123I in humans ~hours!. S.I.—small intestine;
U.L.I.—upper large intestine; L.L.I.—lower large intestine; R.O.C.—
remainder of carcass.
Source regions Females Males
Blood 0.089 0.10
Liver 1.0 0.77
Kidneys 0.36 0.29
Heart 1.1 0.86
Thyroid 1.9 2.2
Brain 2.0 1.9
Stomach wall 0.086 0.079
S.I. wall 0.86 0.67
U.L.I. wall 0.41 0.34
Stomach contents 0.016 0.014
S.I. contents 0.019 0.016
U.L.I. contents 0.038 0.031
L.L.I. contents 0.031 0.026
Ovaries/testes 0.0050 0.010
Uterus 0.048
R.O.C. 6.0 5.5
Urinary bladder contents 0.50 0.58Medical Physics, Vol. 27, No. 4, April 2000would be blocked by saturating the organ with nonradioac-
tive iodine from oral administration of Lugol’s solution. The
absorbed dose to the thyroid after blocking would be ap-
proximately 0.24 mGy/MBq, a 90% dose reduction. The next
highest absorbed dose was in the urinary bladder wall with
an estimated absorbed dose of 0.075 mGy/MBq in males and
0.085 mGy/MBq in females. The G.I. tract organs, which
had unusual kinetics, had absorbed doses ranging from 0.012
to 0.064 mGy/MBq. The whole body effective dose for hu-
mans was 0.16 mSv/MBq for males and 0.14 mSv/MBq for
females.
No significant uncertainty analysis could be performed on
the absorbed dose estimates. It is almost impossible and
meaningless to try to apply a sound uncertainty analysis to
biological data which have been extrapolated across species.
The extrapolation of data from rats to humans, although im-
portant to obtain reliable dose estimates, is very uncertain
when accounting for metabolic differences between the rat
and the human through use of correction factors. Likewise,
application of dose estimates to populations is tenuous be-
cause of individual differences in metabolism, organ masses,
and other physiological parameters. These are the major
problems in relying on animal data to determine absorbed
dose in humans. It has been determined from empirical re-
sults of previous comparisons that extrapolations of organ-
residence times from animals to humans are usually within a
factor of 4, only about 75% of the time.16 This is the best
estimate that can be given for the reliability of dose estimates
TABLE IV. Absorbed radiation dose per unit injected activity ~mGy/MBq! of
123I-PIP ~from the extrapolated model!.
Organ/Tissue Male Female
Liver 0.021 0.033
Kidneys 0.031 0.043
Heart wall 0.072 0.12
Lung 0.0091 0.013
Thyroid 2.4 2.4
Brain 0.055 0.065
Stomach wall 0.019 0.024
Small intestine wall 0.032 0.044
Upper large intestine wall 0.048 0.064
Lower large intestine wall 0.012 0.017
Spleen 0.0082 0.011
Urinary bladder wall 0.075 0.085
Muscle 0.0083 0.011
Pancreas 0.011 0.015
Adrenals 0.010 0.014
Testes 0.011
Breasts 0.0076
Ovaries 0.025
Uterus 0.030
Bone surface 0.016 0.020
Red marrow 0.0084 0.011
Skin 0.0050 0.0062
Thymus 0.010 0.014
Gall bladder wall 0.012 0.018
Remainder 0.011 0.016
Effective Dose 0.16 0.14
~mSv/MBq!
785 Breeden III et al.: In vivo biodistribution 785FIG. 3. Urinary excretion data, decay corrected for 123I
and 125I.for IPIP based on the rat model extrapolated to humans. Sta-
tistical analyses are, however, appropriate in the biodistribu-
tion data. The standard deviations calculated for these data
were relatively small with the exception of the contents of
the G.I. tract organs. This suggests that precision is high for
the methods of organ retrieval, thus adding confidence to the
absorbed dose estimates.
V. CONCLUSIONS
Animal tissue biodistribution and excretion data were ob-
tained and evaluated for IPIP, a new mAChR agent. The
biodistribution studies of the Z-(S)-IPIP stereoisomer sug-
gest that it may be a successful candidate for future brain and
heart imaging in diagnostic nuclear medicine procedures de-
termining muscarinic receptor site function. IPIP also shows
some potential as a therapeutic radiopharmaceutical for some
colon carcinomas where muscarinic receptor sites are ex-
pressed in the tumor cells due to the high uptake in the G.I.
tract. The internal absorbed dose estimates for humans based
on the extrapolated rat model provide reliable preliminary
estimates for initial use of IPIP for routine clinical studies in
humans. The critical organ proved to be the thyroid for this
radiopharmaceutical. The internal dose estimates obtained
from this study are acceptable for the dosimetry required for
Physician-sponsored Investigational New Drug ~IND! appli-
cation’s to the FDA in order to initiate patient Phase I
studies.19 Additionally, validation of this model is critical
and should be carried out at the time of patient trials.
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